Repare Therapeutics, Inc. (“Repare” or “the Company”) is a leading precision medicine oncology company focused on bringing novel synthetic lethality based therapies to patients with cancer. Synthetic lethality, or SL, represents a clinically validated approach to drug development. The Company applies its proprietary genome-wide, CRISPR-enabled platform, SNIPRx, to systematically discover and develop highly targeted cancer therapies focused on genome instability, including DNA damage repair. The Company’s lead product candidate, RP-3500, is a potent and selective inhibitor of ATR, or ataxia telangiectasia and Rad3-related protein, that is being developed for the treatment of tumors with mutations in ATM, or ataxia-telangiectasia mutated kinase, which is an SL pair with ATR.